Furthermore, an animal model demonstrated that ASXL1‐G643W mutations (the most common mutation according to the authors) contributed to the development of CEBPA‐driven AML, which is involved in the resistance to chemotherapy.23, 49. The gene discussed is ASXL1; the disease is acute myeloid leukemia.